AdAlta Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

AdAlta heeft een totaal eigen vermogen van A$2.0M en een totale schuld van A$2.6M, wat de schuld-eigenvermogensverhouding op 128.3% brengt. De totale activa en totale passiva bedragen respectievelijk A$5.6M en A$3.5M.

Belangrijke informatie

128.3%

Verhouding schuld/eigen vermogen

AU$2.61m

Schuld

Rente dekkingsratio	n/a
Contant	AU$3.13m
Aandelen	AU$2.03m
Totaal verplichtingen	AU$3.54m
Totaal activa	AU$5.57m

Recente financiële gezondheidsupdates

Recent updates

Is AdAlta (ASX:1AD) A Risky Investment?

Oct 11

Shareholders May Find It Hard To Justify Increasing AdAlta Limited's (ASX:1AD) CEO Compensation For Now

Nov 16

Is AdAlta (ASX:1AD) Using Debt Sensibly?

Sep 02

We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate

Jun 11

Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth

Feb 26

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( A$5.3M ) 1AD } overtreffen de korte termijn passiva ( A$2.2M ).

Langlopende schulden: De kortetermijnactiva 1AD ( A$5.3M ) overtreffen de langetermijnschulden ( A$1.3M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 1AD heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 1AD is de afgelopen 5 jaar gestegen van 0% naar 128.3%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: 1AD heeft minder dan een jaar aan cash runway op basis van de huidige vrije kasstroom.

Voorspelling contante baan: 1AD heeft minder dan een jaar aan kasmiddelen als de vrije kasstroom blijft dalen met historische percentages van 0 % per jaar.

AdAlta Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is AdAlta (ASX:1AD) A Risky Investment?

Is AdAlta (ASX:1AD) Using Debt Sensibly?

We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate

Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth

Recent updates

AdAlta Limited Appoints Kevin Lynch as Consultant Chief Medical Officer of AdCella

AdAlta Limited, Annual General Meeting, Nov 20, 2024

Is AdAlta (ASX:1AD) A Risky Investment?

New major risk - Shareholder dilution

New major risk - Financial position

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.66 million.

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.66 million.

New major risk - Financial position

AdAlta Limited has filed a Follow-on Equity Offering in the amount of AUD 1.23 million.

AdAlta Limited, Annual General Meeting, Nov 22, 2023

New major risk - Financial position

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 3.153759 million.

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in 1H 2022)

Shareholders May Find It Hard To Justify Increasing AdAlta Limited's (ASX:1AD) CEO Compensation For Now

Less than half of directors are independent

AdAlta Limited Provides an Update on Its Lead Program, AD-214

AdAlta Limited, Annual General Meeting, Nov 22, 2022

AdAlta Limited, Annual General Meeting, Nov 22, 2022

Is AdAlta (ASX:1AD) Using Debt Sensibly?

Full year 2022 earnings released: AU$0.022 loss per share (vs AU$0.024 loss in FY 2021)

AdAlta Limited Modifies the Sequencing of AD-214 Manufacturing Campaigns and Toxicology Studies

Price target increased to AU$0.27

Less than half of directors are independent

Adalta Limited Finalizes Reclinical Development Program to Develop Inhaled Version of AD-214

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.253406 million.

Full year 2021 earnings released: AU$0.024 loss per share (vs AU$0.037 loss in FY 2020)

We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate

First half 2021 earnings released: AU$0.021 loss per share (vs AU$0.037 loss in 1H 2020)

Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth

AdAlta Receives Orphan Drug Designation from the US Food and Drug Administration for Its Lead Product Candidate AD-214 for the Treatment of Idiopathic Pulmonary Fibrosis

AdAlta Limited Announces Phase I HV Extension to Explore Encouraging Results

AdAlta Limited Announces the Extension of its Collaboration with GE Healthcare

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 4.09864 million.

Full year earnings released - AU$0.037 loss per share

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven